Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ballantyne

Showing results (461-470 of 999) with videos related to

Pageof 100
Sort By:
Clinical Biochemistry|November 20, 2013
Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE)Julie K Bower, James S Pankow, Mariana Lazo, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 23, 2014
Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities studyCasey M Rebholz, Brad C Astor, Morgan E Grams, et al.
Cells|June 10, 2022
Poloxamer 407 Induces Hypertriglyceridemia but Decreases Atherosclerosis in Ldlr<sup>-/-</sup> MiceXueying Peng, Zeqin Lian, Xiao-Yuan Dai Perrard, et al.
Journal of the American Geriatrics Society|September 8, 2019
Subclinical Cardiovascular Disease and Fall Risk in Older Adults: Results From the Atherosclerosis Risk in Communities StudyStephen P Juraschek, Natalie Daya, Lawrence J Appel, et al.
The New England Journal of Medicine|March 14, 2019
Safety and Efficacy of Bempedoic Acid to Reduce LDL CholesterolKausik K Ray, Harold E Bays, Alberico L Catapano, et al.
Atherosclerosis|February 1, 2023
Atherosclerotic cardiovascular disease risk and small dense low-density lipoprotein cholesterol in men, women, African Americans and non-African Americans: The pooling projectErnst J Schaefer, Hiroaki Ikezaki, Margaret R Diffenderfer, et al.
Diabetes Care|August 31, 2012
Novel risk factors and the prediction of type 2 diabetes in the Atherosclerosis Risk in Communities (ARIC) studyL A Raynor, James S Pankow, Bruce B Duncan, et al.
Circulation|February 17, 1999
Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapyC M Ballantyne, J A Herd, L L Ferlic, et al.
Journal of Cardiovascular Development and Disease|June 26, 2024
Contrast-Enhanced Magnetic Resonance Imaging Based T1 Mapping and Extracellular Volume Fractions Are Associated with Peripheral Artery DiseaseAsem I Fitian, Michael C Shieh, Olga A Gimnich, et al.
American Heart Journal|April 29, 2006
Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) IIChristie M Ballantyne, Marcelo Bertolami, Hugo Ricardo Hernandez Garcia, et al.
Pageof 100

Showing results (461-470 of 999) with videos related to

Sort By:
Pageof 100
Clinical Biochemistry|November 20, 2013
Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE)Julie K Bower, James S Pankow, Mariana Lazo, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 23, 2014
Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities studyCasey M Rebholz, Brad C Astor, Morgan E Grams, et al.
Cells|June 10, 2022
Poloxamer 407 Induces Hypertriglyceridemia but Decreases Atherosclerosis in Ldlr<sup>-/-</sup> MiceXueying Peng, Zeqin Lian, Xiao-Yuan Dai Perrard, et al.
Journal of the American Geriatrics Society|September 8, 2019
Subclinical Cardiovascular Disease and Fall Risk in Older Adults: Results From the Atherosclerosis Risk in Communities StudyStephen P Juraschek, Natalie Daya, Lawrence J Appel, et al.
The New England Journal of Medicine|March 14, 2019
Safety and Efficacy of Bempedoic Acid to Reduce LDL CholesterolKausik K Ray, Harold E Bays, Alberico L Catapano, et al.
Atherosclerosis|February 1, 2023
Atherosclerotic cardiovascular disease risk and small dense low-density lipoprotein cholesterol in men, women, African Americans and non-African Americans: The pooling projectErnst J Schaefer, Hiroaki Ikezaki, Margaret R Diffenderfer, et al.
Diabetes Care|August 31, 2012
Novel risk factors and the prediction of type 2 diabetes in the Atherosclerosis Risk in Communities (ARIC) studyL A Raynor, James S Pankow, Bruce B Duncan, et al.
Circulation|February 17, 1999
Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapyC M Ballantyne, J A Herd, L L Ferlic, et al.
Journal of Cardiovascular Development and Disease|June 26, 2024
Contrast-Enhanced Magnetic Resonance Imaging Based T1 Mapping and Extracellular Volume Fractions Are Associated with Peripheral Artery DiseaseAsem I Fitian, Michael C Shieh, Olga A Gimnich, et al.
American Heart Journal|April 29, 2006
Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) IIChristie M Ballantyne, Marcelo Bertolami, Hugo Ricardo Hernandez Garcia, et al.
Pageof 100